Stock 0GY1 SWEDISH ORPHAN BIOVITRUM
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

End-of-day quote London S.E.
Other stock markets
- SEK - Intraday chart for SWEDISH ORPHAN BIOVITRUM
07-02 Sweden's Sobi Begins Rolling Application for Gout Treatment in US MT
07-02 Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Invitation: Sobi's Q2 2024 report
PU
Sweden's Sobi Begins Rolling Application for Gout Treatment in US
MT
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
CI
Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
AQ
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct
MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A
CI
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
PU
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024
PU
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress
PU
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB
CI
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GL
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
DJ
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
GL
Bulletin from Sobi's Annual General Meeting (AGM)
AQ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member
CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue
MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy
MT
Sobi has completed SEK 3 billion senior bond issue
AQ
Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
AQ
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. 0GY1 Stock
  5. News SWEDISH ORPHAN BIOVITRUM